Biodexa looks to prevent or delay the worst outcomes for adolescents and young adults with devastating precancerous condition

Registrational phase 3 clinical trials of biodexa's (nasdaq:bdrx) candidate erapa are expected to start first quarter next year. the candidate was developed with private funds and acquired by biodexa, its second portfolio expansion in less than six months, and is supported by a $17 million grant from the state of texas.
BDRX Ratings Summary
BDRX Quant Ranking